Chr t(11;14)

News alerts, weekly reports and conference planners

Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + bortezomib Sensitive: B - Late Trials venetoclax + bortezomib Sensitive : B	venetoclax + bortezomib Sensitive: B - Late Trials venetoclax + bortezomib Sensitive : B
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Resistant: B - Late Trials Resistant : B	Resistant: B - Late Trials Resistant : B
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Resistant: B - Late Trials Resistant : B	Resistant: B - Late Trials Resistant : B
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria venetoclax + atezolizumab + cobimetinib Sensitive : C2	venetoclax + atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria venetoclax + atezolizumab + cobimetinib Sensitive : C2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials BRAF inhibitor + MEK inhibitor Sensitive : C3	BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials BRAF inhibitor + MEK inhibitor Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	BRAF inhibitor Sensitive: C3 – Early Trials BRAF inhibitor Sensitive : C3	BRAF inhibitor Sensitive: C3 – Early Trials BRAF inhibitor Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + cobimetinib Sensitive: C3 – Early Trials venetoclax + cobimetinib Sensitive : C3	venetoclax + cobimetinib Sensitive: C3 – Early Trials venetoclax + cobimetinib Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + daratumumab Sensitive: C3 – Early Trials venetoclax + daratumumab Sensitive : C3	venetoclax + daratumumab Sensitive: C3 – Early Trials venetoclax + daratumumab Sensitive : C3
Chr t(11;14)	Mantle Cell Lymphoma	Chr t(11;14)	Mantle Cell Lymphoma	INCB50465 Sensitive: C3 – Early Trials INCB50465 Sensitive : C3	INCB50465 Sensitive: C3 – Early Trials INCB50465 Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + selinexor Sensitive: C3 – Early Trials venetoclax + selinexor Sensitive : C3	venetoclax + selinexor Sensitive: C3 – Early Trials venetoclax + selinexor Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	BGB-11417 Sensitive: C3 – Early Trials BGB-11417 Sensitive : C3	BGB-11417 Sensitive: C3 – Early Trials BGB-11417 Sensitive : C3
Chr t(11;14)	Leukemia	Chr t(11;14)	Leukemia	DOT1L inhibitor + venetoclax Sensitive: D – Preclinical DOT1L inhibitor + venetoclax Sensitive : D	DOT1L inhibitor + venetoclax Sensitive: D – Preclinical DOT1L inhibitor + venetoclax Sensitive : D
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	APG-2575 Sensitive: D – Preclinical APG-2575 Sensitive : D	APG-2575 Sensitive: D – Preclinical APG-2575 Sensitive : D

Chr t(11;14)

Associations